GlassScriptPhysician profile
Brett J Nile
NPI 1154322014
$10,790.30
in general payments reported to CMS, 2019-2025
45 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $2,023 · 2021: $3,154 · 2022: $1,035 · 2023: $1,308 · 2024: $719 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305 · Honoraria: $31.00 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $305.00 |
| Honoraria | $31.00 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,552.20 | 2020-2021 | |
| Novo Nordisk INC | $1,527.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,442.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,405.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.32 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $655.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Allergan, INC. | $309.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $279.65 | 2019-2021 | |
| Pfizer INC. | $275.61 | 2019-2025 | |
| Genzyme Corporation | $240.00 | 2020 | |
| Glaxosmithkline, LLC. | $230.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $202.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $184.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $151.05 | 2020-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Nile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.